Cost-Effectiveness Analysis of Nivolumab Plus Ipilimumab for Advanced Non-Small-Cell Lung Cancer

• Autors principals: Xiaomin Wan (Autor), Xiaohui Zeng (Autor), Liubao Peng (Autor), Ye Peng (Autor), Qiao Liu (Autor), Lidan Yi (Autor), Xia Luo (Autor), Qijian Deng (Autor), Chongqing Tan (Autor)
• Format: Llibre
• Publicat: Frontiers Media S.A., 2021-08-01T00:00:00Z.
• Matèries: article
• Accés en línia: Connect to this object online.

Objective: This study evaluated the cost-effectiveness of nivolumab plus ipilimumab vs. chemotherapy in the first-line setting for patients with advanced non-small-cell lung cancer (NSCLC) from the US payer perspective.Materials and methods: A Markov model wasdeveloped to evaluate the cost and effec...